• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].《GATTO研究的勘误：一项Ib期研究，将抗TA-MUC1抗体Gatipotuzumab与抗EGFR抗体Tomuzotuximab联合用于难治性实体瘤患者》：[《ESMO Open》第7卷，第2期，2022年4月，100447]
ESMO Open. 2022 Aug;7(4):100549. doi: 10.1016/j.esmoop.2022.100549. Epub 2022 Jul 13.
2
Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors.GATTO 研究的安全性和初步活性结果，这是一项 Ib 期研究，将抗-TA-MUC1 抗体 gatipotuzumab 与抗-EGFR tomuzotuximab 联合用于治疗难治性实体瘤患者。
ESMO Open. 2022 Apr;7(2):100447. doi: 10.1016/j.esmoop.2022.100447. Epub 2022 Apr 6.
3
Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. gatipotuzumab 表位 TA-MUC1 与卵巢癌雌激素受体的潜在相互作用。
Int J Mol Sci. 2019 Jan 12;20(2):295. doi: 10.3390/ijms20020295.
4
TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.由完全人源化的治疗性抗体 Gatipotzumab 检测到的 TA-MUC1 预测宫颈癌预后不良。
J Cancer Res Clin Oncol. 2018 Oct;144(10):1899-1907. doi: 10.1007/s00432-018-2706-5. Epub 2018 Jul 30.
5
Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study.抗肿瘤相关粘蛋白 1 抗体 gatipotuzumab 用于复发性上皮性卵巢癌患者的维持治疗：一项双盲、安慰剂对照、随机、Ⅱ期研究结果。
ESMO Open. 2022 Feb;7(1):100311. doi: 10.1016/j.esmoop.2021.100311. Epub 2021 Dec 15.
6
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas.针对晚期癌症患者开展的tomuzotuximab（一种糖基工程化抗表皮生长因子受体治疗性抗体）的I期研究。
ESMO Open. 2018 Feb 1;3(2):e000303. doi: 10.1136/esmoopen-2017-000303. eCollection 2018.
7
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.一项比较糖基优化型抗 EGFR 抗体 tomuzotuximab 与 cetuximab 在复发性和/或转移性头颈部鳞状细胞癌患者中的疗效和安全性的随机 II 期研究 - RESGEX 研究。
ESMO Open. 2021 Oct;6(5):100242. doi: 10.1016/j.esmoop.2021.100242. Epub 2021 Sep 2.
8
Evaluation of Safety of Treatment With Anti-Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid Tumors: A Phase 1 Nonrandomized Clinical Trial.抗表皮生长因子受体抗体药物偶联物 MRG003 治疗晚期实体瘤患者的安全性评价：一项 1 期非随机临床试验。
JAMA Oncol. 2022 Jul 1;8(7):1042-1046. doi: 10.1001/jamaoncol.2022.0503.
9
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma.GLS-010（一种用于晚期实体瘤或淋巴瘤的重组全人抗程序性死亡-1单克隆抗体）的剂量递增与扩展（Ia/Ib期）研究
Eur J Cancer. 2021 May;148:1-13. doi: 10.1016/j.ejca.2021.01.020. Epub 2021 Mar 7.
10
EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.EP3 受体是 TA-MUC1 阴性卵巢癌的预后因素。
J Cancer Res Clin Oncol. 2019 Oct;145(10):2519-2527. doi: 10.1007/s00432-019-03017-8. Epub 2019 Sep 4.

引用本文的文献

1
Mucin-1: a promising pan-cancer therapeutic target.粘蛋白-1：一个有前景的泛癌治疗靶点。
NPJ Precis Oncol. 2025 Jul 2;9(1):218. doi: 10.1038/s41698-025-01016-2.
2
Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management.曲妥珠单抗-德鲁替康在晚期乳腺癌中的安全性：不良事件管理的专家意见。
Clin Transl Oncol. 2024 Jul;26(7):1539-1548. doi: 10.1007/s12094-024-03383-x. Epub 2024 Feb 9.

Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447].

作者信息

Ochsenreither S, Fiedler W M, Del Conte G, Macchini M, Matos I, Habel B, Ahrens-Fath I, Raspagliesi F, Lorusso D, Keilholz U, Rolling C, Kebenko M, Klinghammer K F, Saavedra O, Baumeister H, Zurlo A, Garralda A

机构信息

Charité Comprehensive Cancer Center, Berlin; Charité, Department of Hematology, Oncology and Tumor Immunology, Berlin; German Cancer Consortium (DKTK), Berlin.

University Medical Center Hamburg-Eppendorf, Hubertus-Wald University Cancer Center, Hamburg, Germany.

出版信息

ESMO Open. 2022 Aug;7(4):100549. doi: 10.1016/j.esmoop.2022.100549. Epub 2022 Jul 13.

DOI:10.1016/j.esmoop.2022.100549
PMID:35841804
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9293584/
Abstract
摘要